Phoenix Children’s Hospital Standardizes on Masimo
PHOENIX and IRVINE, Calif., Sept. 4, 2012 /PRNewswire/ — Phoenix Children’s Hospital, ranked among the top 50 children’s hospitals across four medical specialties by U.S. News & World Report (2012-2013), and Masimo (NASDAQ: MASI) today announced the hospital’s conversion to Masimo SET(®) pulse oximetry, offering clinicians advanced noninvasive and continuous patient monitoring designed to improve patient outcomes and reduce cost of care.
“As one of the leading children’s hospitals in the nation, we take to heart our obligation to provide the best care for all of our young patients,” said Christine Tenaglia, Respiratory Care Director at Phoenix Children’s Hospital. “Our conversion to Masimo’s state-of-the-art pulse oximetry arms our clinicians with monitoring equipment that can measure accurately even when patients move or have low perfusion – capabilities unmatched by competing pulse oximeters. We tried other pulse oximeters, but have found Masimo’s technology to be more accurate, even under demanding conditions.”
Phoenix Children’s five-year contract for Masimo SET(®) pulse oximetry includes the bedside Rad-87(®) pulse oximeter and the handheld or bedside Radical-7(TM) Pulse CO-Oximeter(®). The hospital also plans to upgrade to Masimo rainbow(®) technology to noninvasively monitor total hemoglobin (SpHb(®)).
Masimo SET(®) virtually eliminates false alarms(1) and increases a clinician’s ability to detect life-threatening events(2). More than 100 independent clinical studies have confirmed that Masimo SET(®) technology allows clinicians to accurately monitor blood oxygen saturation in the most challenging conditions – establishing the technology as the industry-leading pulse oximetry that substantially contributes to improved patient outcomes.
Phoenix Children’s – with more than 12,500 annual admissions, 57,000+ emergency room visits, and more than 15,200 specialty and urgent care visits – offers world-class care in more than 40 subspecialty fields of pediatric medicine, including six Centers of Excellence.
“We treat more young patients than any hospital in our area,” said Tenaglia. “Masimo pulse ox technology allows us to obtain accurate readings, even on our most fidgety patients – an important factor when dealing with the sheer volume we see on any given day. Masimo’s technology also has decreased the frequency of false alarms. That means we can do our jobs better and more efficiently, rather than responding to nuisance alarms.”
1 Shah N, Ragaswamy H, Govindugari K, Estanol L. “Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers.” Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. “Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study.” Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here
About Phoenix Children’s Hospital
Phoenix Children’s Hospital, ranked in U.S. News & World Report‘s Best Children’s Hospitals, is Arizona’s only licensed children’s hospital, providing world-class care in more than 40 pediatric specialties to children from throughout the state and region. Phoenix Children’s is in the midst of a major expansion to meet the needs of the Southwest’s rapid population growth. The signature element of the expansion is a new 11-story, 750,000-square-foot tower which will enable the hospital to grow from 345 licensed beds today to a total of 626 licensed beds once the project is complete. The hospital’s expansion also includes an aggressive physician recruitment effort and new satellite centers in high growth areas of the Valley. For more information, visit the hospital’s web site at www.phoenixchildrens.com.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care–helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET(®), which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET(®) outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET(®) Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb(®)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(®)), methemoglobin (SpMet(®)), and Pleth Variability Index (PVI(®)), in addition to SpO(2), pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet(TM), a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow(®) Acoustic Monitoring(TM), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa(TM)). Masimo’s rainbow(®) SET(®) technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. In 2010, Masimo acquired SEDLine(®), a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET(®) and Masimo rainbow(®) SET(®) technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications(®).” Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including: total hemoglobin (SpHb(®)), PVI(®), acoustic respiration rate (RRa(TM)), and SEDLine(®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC“), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts: Jane Walton Mike Drummond Phoenix Children's Hospital Masimo Corporation Phone: (602) 933-5871 Phone: (949) 297-7434 Email: email@example.com Email: firstname.lastname@example.org
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.